X

inositol-blood-pressure

The Combined Therapy With Myo-inositol And D-chiro-inositol Reduces The Risk Of Metabolic Disease In PCOS Overweight Patients Compared To Myo-inositol Supplementation Alone

効果 減少
試験方法 コホート法
試験期間 6+ ヶ月
被験者数 50
性別 女性
年齢 18-29, 30-44
体型 肥満
この研究の注釈:

Supplementation of myo-inositol by itself at 2g daily for a period of six months in women with PCOS was associated with improvements in diastolic blood pressure. The combination with D-chiroinositol was the same at a lower dose (550mg and 13.8mg, respectively) when measured at six months, but seemed to act faster as inositol at 2g required six months to be fully effective.


Effects Of D-chiro-inositol In Lean Women With The Polycystic Ovary Syndrome
効果 減少
試験方法 二重盲検法
試験期間 1-6 ヶ月
被験者数 20
性別 女性
年齢 18-29, 30-44
体型 平均
この研究の注釈:

6-8 weeks of supplementation with 600mg D-chiro-inositol daily in women with PCOS who also had an average BMI was able to increase ovulation secondary to reducing androgens, and appears to be effective in improving other biomarkers of health such as blood pressure and triglycerides.


Metabolic And Hormonal Effects Of Myo-inositol In Women With Polycystic Ovary Syndrome: A Double-blind Trial
効果 減少
試験方法 二重盲検法
試験期間 1-6 ヶ月
被験者数 42
性別 男女
年齢 18-29, 30-44
体型 肥満
この研究の注釈:

Supplementation of 4,000mg inositol daily for a period of 12-16 weeks in women with PCOS was able to improve tolerance to glucose and glucose handling (as well as reduce the amount of insulin secreted in response to a meal) with minor benefits to cardiovascular health as well.


One-year Effects Of Myo-inositol Supplementation In Postmenopausal Women With Metabolic Syndrome
効果 減少
試験方法 二重盲検法
試験期間 6+ ヶ月
被験者数 80
性別 女性
年齢 45-64, 65+
体型 肥満
この研究の注釈:

Supplementation of myo-inositol at 2g twice daily for the course of one year in postmenopausal women with metabolic syndrome was associated with improvements on all metabolic parameters measured (cardiovascular health and glucose metabolism) although no influence on weight was noted.


Myo-inositol Treatment Increases Serum Plasmalogens And Decreases Small Dense LDL, Particularly In Hyperlipidemic Subjects With Metabolic Syndrome
効果 なし
試験方法 コホート法
試験期間 1-2 週間
被験者数 17
性別 男女
年齢 30-44, 45-64
体型 肥満
この研究の注釈:

Two weeks supplementation of _myo_-inositol at 5g (first week) and 10g (second week) was able to increase circulating levels of choline plasmalogen, which is thought to be the reason behind a reduction in LDL-C. These changes were not present in persons without metabolic syndrome.


Myo-inositol Treatment Increases Serum Plasmalogens And Decreases Small Dense LDL, Particularly In Hyperlipidemic Subjects With Metabolic Syndrome
効果 減少
試験方法 コホート法
試験期間 1-2 週間
被験者数 17
性別 男女
年齢 30-44, 45-64
体型 肥満
この研究の注釈:
スポンサーリンク

Two weeks supplementation of _myo_-inositol at 5g (first week) and 10g (second week) was able to increase circulating levels of choline plasmalogen, which is thought to be the reason behind a reduction in LDL-C. These changes were not present in persons without metabolic syndrome.


管理人 :慶應義塾大学の理工学部卒業後、国内外でコンサルティング業務やスタートアップの立ち上げを経験した後、日本に帰国してから健康・医療の情報を収集して発信しています。 趣味:ネットサーフィン、読書(最近かなり減ってますが)、アウトドア(家族と) 毎日メディテーションとジョギング、筋トレ・ストレッチしています。既婚で子供4人(男女女男)です。